Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary treatment. Llusern’s Lodestar DX changes that: a point-of-care test that detects 96% of key UTI pathogens in just 35 minutes, no lab required. In this episode I’m joined by Emma Hayhurst who shares her journey into diagnostics, Llusern’s mission, and the...
All content for Beyond Biotech - the podcast from Labiotech is the property of Labiotech and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary treatment. Llusern’s Lodestar DX changes that: a point-of-care test that detects 96% of key UTI pathogens in just 35 minutes, no lab required. In this episode I’m joined by Emma Hayhurst who shares her journey into diagnostics, Llusern’s mission, and the...
Next‑generation UTI diagnostics: delivering results in just 35 minutes
Beyond Biotech - the podcast from Labiotech
39 minutes
1 week ago
Next‑generation UTI diagnostics: delivering results in just 35 minutes
Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary treatment. Llusern’s Lodestar DX changes that: a point-of-care test that detects 96% of key UTI pathogens in just 35 minutes, no lab required. In this episode I’m joined by Emma Hayhurst who shares her journey into diagnostics, Llusern’s mission, and the...
Beyond Biotech - the podcast from Labiotech
Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary treatment. Llusern’s Lodestar DX changes that: a point-of-care test that detects 96% of key UTI pathogens in just 35 minutes, no lab required. In this episode I’m joined by Emma Hayhurst who shares her journey into diagnostics, Llusern’s mission, and the...
